Immigration program, EB-5, was reformed over a year ago. II USA’s Aaron Grau talks about the state of the program after changes have been made.

Sponsored Content. Fortress Information Security’s CEO, Alex Santos on the latest tools in battling hackers looking to take down America’s electric utilities.

IIUSA’s Aaron Grau and Rajvir Batra of the American Immigrant Investor Association discuss the just renewed EB-5 immigration program.

A discussion with Fortress Information Security’s John Cofrancesco on meeting the challenges of cyber attacks.

The latest on the vaccines, variants and government performance with Dr. Sonja Rasmussen.

Accident Theory - COVID and spectacular industrial mishaps. Inevitable or avoidable?

Dr. Robert Meyers explains how Accident Theory integrates errors in the complex systems that run the world.

HPN sits down for another conversation with former CDC pandemic specialist Dr. Sonja Rasmussen to discuss the U.S. response to COVID-19 over the past six months.

Healthcare Ready commissioned a survey that asked about American readiness for natural disasters and pandemics. HPN’s podcast with CEO Dr. Nicolette Louissaint reveals some of the highlights.

America’s public health system has been chronically underfunded. We’re paying the price now. Find out how. A conversation with John Auerbach, CEO of The Trust for America’s Health.

The Trust for America’s Health looks at the nation’s public health system. Each year they publish an assessment of the soundness of our healthcare infrastructure. This year’s report was not kind.


Among the topics discussed:

- Areas that are facing the greatest deficits in funding
- Dealing with elected officials who are reluctant to fund programs without immediate returns.
- Who is really on the front line: the states or the Feds
- Impact of a shrinking public health workforce

Sarah Lofgren is part of a team of researchers conducting a trial of hydroxychloroquine. Working out of the University of Minnesota, the team is providing the drug to first responders to assess the impact in preventing the onset of COVID-19 as well as the drug’s ability to mitigate the more severe symptoms of the disease.


In this episode, we discuss:

- The impact of anecdotal evidence of hydroxychloroquine’s usage around the world
- If pandemics offer an excuse to relax drug approval protocols
- Why use First Responders in a hydroxychloroquine trial
- If therapies like hydroxychloroquine provide enough breathing space to get America back to work